吉列替尼联合VAA方案治疗FLT3-ITD突变的难治性急性髓系白血病1例并文献复习

李可昕; 盘婉盈; 吴少杰; 黄宇贤

doi:10.13201/j.issn.1004-2806.2021.03.012

吉列替尼联合VAA方案治疗FLT3-ITD突变的难治性急性髓系白血病1例并文献复习

- 南方医科大学珠江医院(广州, 510280)
基金项目:
国家自然科学基金资助项目(No:81302372)

详细信息

通讯作者: 黄宇贤,E-mail:hyx6610@163.com

中图分类号: R733.71

收稿日期: 2019-05-07

Gilteritinib combined with VAA regimen in the treatment of refractory acute myeloid leukemia with FLT3-ITD mutation and literature review

More Information

Corresponding author: HUANG Yuxian, E-mail: hyx6610@163.com

Received Date: 07 May 2019

摘要

- FLT3-ITD突变 /
- FLT3抑制剂 /
- 难治性急性髓系白血病 /
- 维克特拉 /
- 吉列替尼
Abstract: The clinical and laboratory characteristics of a patient with refractory acute myeloid leukemia combined with FLT3-ITD positive were reported. The patient received gilteritinib combination therapy. After treated with the combination of gilteritinib and VAA(venetoclax plus azacitidine and low-dose cytarabine) regimen, the patient achieved complete remission and obtained the time to complete the hematopoietic stem cell transplant. No serious adverse events were observed during oral gilteritinb or venetoclax, suggesting that gilteritinb combined with VAA regimen is safe and effective in the treatment of refractory acute myeloid leukemia with FLT3-ITD mutation.
- FLT3-ITD mutation /
- FLT3 inhibitors /
- refractory acute myeloid leukemia /
- venetoclax /
- gilteritinib

HTML全文

参考文献(13)

[1]	Liang CA,Chen L,Wahed A,et al.Proteomics Analysis of FLT3-ITD Mutation in Acute Myeloid Leukemia Using Deep Learning Neural Network[J].Ann Clin Lab Sci,2019,49(1):119-126.
[2]	盘婉盈,李可昕,黄宇贤.吉列替尼治疗FLT3突变急性髓系白血病研究进展[J].临床血液学杂志,2020,33(11):807-810.
[3]	Kenins L,Gill JW,HollanderGA,et al.Flt3 ligand-receptor interaction is important for maintenance of early thymic progenitor numbers in steady-state thymopoiesis[J].Eur J Immunol,2010,40(1):81-90.
[4]	Short NJ,Kantarjian H,Ravandi F,et al.Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia[J].Ther Adv Hematol,2019,10:2040620719827310.
[5]	Ma J,Dunlap J,Paliga A,et al.DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML[J].Leuk Lymphoma,2018,59(8):1938-1948.
[6]	Schlenk RF,Muller-Tidow C,Benner A,et al.Relapsed/refractory acute myeloid leukemia:any progress?[J].Curr Opin Oncol,2017,29(6):467-473.
[7]	夏训明.美国FDA批准Xospata(gilteritinib)治疗FLT3基因变异型急性髓细胞白血病[J].广东药科大学学报,2018,34(6):713-713.
[8]	Perl AE,Altman JK,Cortes J.Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia:a multicentre,first-in-human,open-label,phase 1-2 study[J].Lancet Oncol,2017,18(12):E711-E711.
[9]	Perl AE,Martinelli G,Cortes JE.Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML[J].N Engl J Med,2019,381(18):1728-1740.
[10]	Rashidi A,Weisdorf DJ,Bejanyan N.Treatment of relapsed/refractory acute myeloid leukaemia in adults[J].Br J Haematol,2018,181(1):27-37.
[11]	Gorcea CM,Burthem J,Tholouli E.ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation:background and design of the ADMIRAL trial[J].Future Oncol,2018,14(20):1995-2004.
[12]	DiNardo CD,Pratz KW,Letai A.Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia:a non-randomised,open-label,phase 1b study[J].Lancet Oncol,2018,19(2):216-228.
[13]	Jetani H,Garcia-Cadenas I,Nerreter T,et al.CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+)AML and act synergistically with the FLT3-inhibitor crenolanib[J].Leukemia,2018,32(5):1168-1179.